Articles

• Introduction

  Douglas E. Joshua

  https://doi.org/10.4081/hmr.v1i11.349

  147

  PDF: 118

  • PDF

• Thalidomide alone or in combination: results in refractory patients

  Jesús F. San Miguel

  https://doi.org/10.4081/hmr.v1i11.350

  235

  PDF: 364

  • PDF

• Retrospective study of thalidomide plus dexamethasone versus conventional chemotherapy in the relapsed multiple myeloma patient and the study of melphalan and prednisone versus melphalan, prednisone, and thalidomide

  Mario Boccadoro

  https://doi.org/10.4081/hmr.v1i11.351

  152

  PDF: 169

  • PDF

• The Intergroupe Francophone du Myélome experience with thalidomide

  Jean-Luc Harousseau, Michel Attal, Thierry Facon, Ibrahim Yakoub-Agha

  https://doi.org/10.4081/hmr.v1i11.352

  191

  PDF: 284

  • PDF

• Thalidomide plus dexamethasone as initial therapy for multiple myeloma: overview of Mayo Clinic and Eastern Cooperative Oncology Group experience

  Robert A. Kyle, Vincent Rajkumar

  https://doi.org/10.4081/hmr.v1i11.353

  155

  PDF: 273

  • PDF

• Panel Discussion

  Dr. Joshua

  https://doi.org/10.4081/hmr.v1i11.354

  134

  PDF: 196

  • PDF